Exact Sciences Corporation (EXAS) Plunges 5.39% on September 27

Exact Sciences Corporation (EXAS) Plunges 5.39% on September 27

Exact Sciences Corporation (EXAS) had a rough trading day for Friday September 27 as shares tumbled 5.39%, or a loss of $-5.24 per share, to close at $92.00. After opening the day at $97.02, shares of Exact Sciences Corporation traded as high as $97.76 and as low as $91.54. Volume was 2.73 million shares over 25,072 trades, against an average daily volume of n/a shares and a total float of 129.49 million.

As a result of the decline, Exact Sciences Corporation now has a market cap of $11.91 billion. In the last year, shares of Exact Sciences Corporation have traded between a range of $123.99 and $53.06, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of certain types of cancer. Its core product is a noninvasive screening test, Cologuard, which analyzes stool-based DNA samples to detect the precancerous and early stages of colorectal cancer. The test includes DNA markers and a protein marker that can detect blood in the stool. Exact Sciences receives revenue from two sources: laboratory services and licensing fees. Its laboratory services revenue is generated by diagnostic services that use the Cologuard test. Exact Sciences also receives revenue from the licensing of its product rights.

Exact Sciences Corporation is based out of Madison, WI and has some 1,977 employees. Its CEO is Kevin T. Conroy.

error: Content is protected !!